34.92
-0.99 (-2.76%)
| Penutupan Terdahulu | 35.91 |
| Buka | 35.50 |
| Jumlah Dagangan | 1,134,404 |
| Purata Dagangan (3B) | 1,432,817 |
| Modal Pasaran | 5,513,762,816 |
| Harga / Pendapatan (P/E Ke hadapan) | 90.91 |
| Harga / Jualan (P/S) | 6.65 |
| Harga / Buku (P/B) | 8.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -44.96% |
| Margin Operasi (TTM) | -29.34% |
| EPS Cair (TTM) | -2.52 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 753.05% |
| Nisbah Semasa (MRQ) | 7.61 |
| Aliran Tunai Operasi (OCF TTM) | -345.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -211.82 M |
| Pulangan Atas Aset (ROA TTM) | -7.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -105.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ionis Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.60 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.78% |
| % Dimiliki oleh Institusi | 98.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tweedy, Browne Co Llc | 30 Sep 2024 | 3,454,676 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 77.00 (Wells Fargo, 120.50%) | Beli |
| Median | 63.50 (81.84%) | |
| Rendah | 60.00 (Needham, 71.82%) | Beli |
| Purata | 66.00 (89.00%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 37.35 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 20 Dec 2024 | 60.00 (71.82%) | Beli | 35.63 |
| 07 Nov 2024 | 60.00 (71.82%) | Beli | 38.46 | |
| Piper Sandler | 14 Nov 2024 | 62.00 (77.55%) | Beli | 37.23 |
| Wells Fargo | 07 Nov 2024 | 77.00 (120.50%) | Beli | 38.46 |
| Guggenheim | 09 Oct 2024 | 65.00 (86.14%) | Beli | 38.06 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HAYDEN MICHAEL R | 36.08 | - | 5,000 | 180,400 |
| Jumlah Keseluruhan Kuantiti Bersih | 5,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 180,400 | |||
| Purata Pembelian Keseluruhan ($) | 36.08 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HAYDEN MICHAEL R | Pengarah | 23 Dec 2024 | Beli (+) | 5,000 | 36.08 | 180,400 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Dec 2024 | Pengumuman | TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet |
| 07 Nov 2024 | Pengumuman | Ionis to present at upcoming investor conferences |
| 06 Nov 2024 | Pengumuman | Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome |
| 06 Nov 2024 | Pengumuman | Ionis reports third quarter 2024 financial results |
| 04 Nov 2024 | Pengumuman | Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE |
| 23 Oct 2024 | Pengumuman | Ionis to hold third quarter 2024 financial results webcast |
| 21 Oct 2024 | Pengumuman | WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |